<DOC>
	<DOCNO>NCT02348021</DOCNO>
	<brief_summary>Prospective , multi-center , non-randomized , open-label trial design enroll 139 patient Japan . All patient receive DCS follow 2 year .</brief_summary>
	<brief_title>Leaders Free Japan</brief_title>
	<detailed_description>In study patient receive Drug Coated Stent receive one month Dual Anti Platelet Therapy .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Any indication PCIS patient deem high risk bleed candidate 1 month DAPT . This include candidate stable angina , silent ischemia , ACS ( STEMI nonSTEMI ) , nonnative lesion instent restenosis . Patients must provide write informed consent . Reasons unsuitability &gt; 1 month dual antiplatelet treatment must include one MORE following : 1 . Adjunctive oral anticoagulation treatment plan continue PCI 2 . Age â‰¥ 75 year old 3 . Baseline Hgb &lt; 11 g/dl ( anemia require transfusion 4 week prior enrollment ) 4 . Any prior intracerebral bleed 5 . Any stroke last 12 month 6 . Hospital admission bleed prior 12 month 7 . Non skin cancer diagnose treat &lt; 3 year 8 . Planned daily NSAID ( aspirin ) steroids &gt; 30 day PCI 9 . Planned surgery would require interruption DAPT ( within next 12 month ) 10 . Renal failure define : Creatinine clearance &lt; 40 ml/min 11 . Thrombocytopenia ( PLT &lt; 100,000/mm3 ) 12 . Severe chronic liver disease define : patient develop follow : variceal hemorrhage , ascites , hepatic encephalopathy jaundice 13 . Expected noncompliance prolonged DAPT medical reason 1 . Pregnant breastfeed woman 2 . Patients expect comply 30 day DAPT 3 . Patients require plan stag PCI procedure one week index procedure 4 . Procedure plan require nonstudy stent , standalone POBA standalone atherectomy 5 . Active bleeding time inclusion 6 . Reference vessel diameter &lt; 2.25 ~ &gt; 4.0mm 7 . Cardiogenic shock 8 . Compliance longterm single antiplatelet therapy unlikely 9 . A known hypersensitivity contraindication aspirin , clopidogrel P2Y12 inhibitor ( applicable ) , stainless steel , zinc , Biolimus A9 sensitivity contrast medium , adequately premedicated 10 . PCI previous 12 month lesion target lesion index procedure 11 . Participation another clinical trial ( 12 month index procedure ) 12 . Patients life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>